Endometrioid Ovarian Cancer Presents Earlier, Offers Better Survival Than Serous Carcinoma

Article

Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.

Women with endometrioid ovarian cancer present at a younger age and with earlier stage disease than those with serous ovarian cancer, according to a new analysis. The earlier presentation resulted in better 5- and 10-year overall survival rates as well.

Endometrioid carcinoma accounts for about 20% of all epithelial ovarian cancers. “The prognostic significance of histologic subtype is controversial, given the relative rarity of histologic subtypes other than serous,” wrote study authors led by Lilian T. Gien, MD, MSc, of the University of Toronto.

The new study was a retrospective analysis of 533 women with ovarian cancer diagnosed at a single center between 1988 and 2006. Of those, 98 women (18.4%) had endometrioid histology, and 435 women (81.6%) had serous histology. Researchers compared these cohorts with regard to presentation, treatment, and survival; the results were published online ahead of print in the Journal of Obstetrics and Gynaecology Canada.

At the time of diagnosis, endometrioid patients were a median age of 50 years, compared with 58 years for serous patients (P < .001). They also presented at an earlier stage of disease, with 83.7% of endometrioid patients presenting with stage I or II vs only 13.8% of serous patients (P < .001).

Almost all endometrioid histology patients (98%) underwent surgery as their primary treatment, compared with 69% of serous patients (P < .001). Most serous patients (97.2%) received adjuvant chemotherapy, compared with 57.1% of endometrioid patients.

Recurrences were more common in serous patients, with 70.1% experiencing a recurrence during the study period compared with 31.6% of endometrioid patients. Among those who did recur, 48.4% of endometrioid patients had the recurrence within the pelvis alone, compared to only 17.9% of serous patients, in whom abdominal recurrences were more likely.

There were 361 total deaths over the median follow-up period of 9.1 years; 26 of the endometrioid patients died (29.6%), and 355 of the serous patients died (77%). The 5-year overall survival rate was 80.6% in women with endometrioid carcinoma, compared with 35% in those with serous disease. At 10 years, these rates were 68.4% and 18.4%, respectively.

On a multivariate analysis that adjusted for age at diagnosis, tumor grade, and treatment variables, the hazard ratio (HR) for death from endometrioid carcinoma compared to serous carcinoma was 0.41 (95% CI, 0.26–0.66; P < .001). When tumor stage was added to that model, the HR was no longer significant, at 0.74 (95% CI, 0.45–1.24; P = 0.26). Adding tumor stage to a model for recurrence risk also attenuated the result.

“This demonstrates that stage of disease at presentation has a profound effect on overall survival and disease-free survival,” the authors wrote, though they noted that it remains unknown exactly why the two histologies tend to present at different stages. “There is a need for further exploration of molecular markers and biologic pathways to better characterize the behavior of these rare histologic subtypes. This will allow us to develop targeted therapies, improve treatment strategies, and improve survival rates and control recurrences.”

Related Videos
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content